TARO-ANASTROZOLE TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

ANASTROZOLE

Saadav alates:

TARO PHARMACEUTICALS INC

ATC kood:

L02BG03

INN (Rahvusvaheline Nimetus):

ANASTROZOLE

Annus:

1MG

Ravimvorm:

TABLET

Koostis:

ANASTROZOLE 1MG

Manustamisviis:

ORAL

Ühikuid pakis:

30

Retsepti tüüp:

Prescription

Terapeutiline ala:

ANTINEOPLASTIC AGENTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0128681001; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2012-10-25

Toote omadused

_Taro-Anastrozole Product Monograph _
_Page 1 of 53 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
TARO-ANASTROZOLE
Anastrozole Tablets
Tablet, 1 mg, Oral
Non-steroidal Aromatase Inhibitor
Taro Pharmaceuticals Inc.
Date of Initial Authorization:
130 East Drive
OCT 25, 2012
Brampton, Ontario
L6T 1C1
Date of Revision:
March 1, 2023
Submission Control No: 271438
_Taro-Anastrozole Product Monograph _
_Page 2 of 53 _
RECENT MAJOR LABEL CHANGES
7. WARNINGS AND PRECAUTIONS, Muscoloskeletal
03/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
.................................................................................................................
4
1.1
Pediatrics:
............................................................................................................................
4
1.2
Geriatrics:
............................................................................................................................
4
2
CONTRAINDICATIONS
....................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
................................................................ 4
4
DOSAGE AND ADMINISTRATION
....................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
................................................................... 5
4.4
Administration
....................................................................................................................
5
4.5
Missed Dose
..................................